Kaya Holdings Advocates For Psilocybin As FDA Rejects MDMA For PTSD Treatment
Kaya Holdings, Inc. (OTCQB:KAYS), a company engaged in the emerging psilocybin treatment sector and medical/recreational cannabis, has voiced strong criticism of the FDA’s decision to reject MDMA therapy as a treatment for post-traumatic stress disorder (PTSD). KAYS, which operates The Sacred Mushroom, a psilocybin treatment facility in Portland, Oregon, advocates for psilocybin therapy as an alternative treatment for PTSD. It is extending an open invitation to those seeking this form of therapy under Oregon law.
CEO’s Response To FDA’s Decision
KAYS’ CEO, Craig Frank, expressed disappointment with the FDA’s decision. “We are deeply sorry the FDA has decided against MDMA use for the treatment of PTSD and regret the impact this may have on developing a PTSD treatment needed …